key: cord-0867301-2kv9ua1j
authors: Khan, Muhammad Shahzeb; Vaduganathan, Muthiah
title: What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?
date: 2020-10-11
journal: Curr Diab Rep
DOI: 10.1007/s11892-020-01347-3
sha: c8555209c76eeedc21fee5c7e0191e540947a496
doc_id: 867301
cord_uid: 2kv9ua1j

PURPOSE OF REVIEW: We highlight the unique properties of the sodium-glucose cotransporter-2 (SGLT-2 inhibitors) which may lend favorably to their efficient integration in the background of other heart failure (HF) therapies. We also discuss the unique aspects of SGLT-2 inhibitor dosing, lack of titration needs, effects on kidney function and electrolytes, diuretic activity, and safety in the high-risk peri-hospitalization window. RECENT FINDINGS: Dapagliflozin was recently approved for the treatment of heart failure with reduced ejection fraction (HFrEF), irrespective of the presence or absence of type 2 diabetes mellitus (T2DM) based on the findings of the pivotal DAPA-HF trial. All SGLT-2 inhibitors are once daily medications with minimal drug-drug interactions and do not require titration (for HF treatment) unlike other HF medications. SGLT-2 inhibitors offer modest weight loss and blood pressure reduction without major adverse effects of hyperkalemia, making it ideal for near-simultaneous initiation with other HF medications, and use in high-risk populations (including older adults). Moreover, SGLT-2 inhibitors appear to afford long-term kidney protection in diverse populations. SUMMARY: SGLT-2 inhibitors are the latest class of therapies to demonstrate important clinical benefits among patients with HFrEF, and their pharmacological properties favor ease of use and integration in multi-drug disease-modifying regimens.

There are approximately 500 million patients with type 2 diabetes mellitus (T2DM) and 64 million patients with heart failure (HF) globally [1, 2] . T2DM and HF often co-exist with one causing a worse prognosis in the other [3, 4] . Antihyperglycemic therapies such as thiazolidinediones and saxagliptin may increase HF events and thus are discouraged among patients with established HF [5, 6] . Other therapies such as the glucagon-like peptide-1 receptor agonists (GLP-1 RA) appear to primarily target atherosclerotic disease pathways while minimally altering pathways that affect HF events.

The sodium-glucose cotransporter-2 (SGLT2) inhibitors have been shown to reduce risk of HF events among various at-risk populations with T2DM (Table 1) [7] [8] [9] 10 ••]. SGLT-2 inhibitors block reabsorption of filtered glucose in the proximal renal tubule causing increased excretion of glucose in the urine, but they appear to have broader multi-system metabolic benefits. Four SGLT-2 inhibitors have been approved by the US Food and Drug Administration (FDA) for use in glycemic control for T2DM. In the landmark DAPA-HF trial (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure), dapagliflozin reduced the composite endpoint of worsening HF events or cardiovascular death by 26% compared with placebo among patients with chronic HF with reduced ejection fraction (HFrEF), irrespective of T2DM status [10••] . Based on these data, dapagliflozin has now been approved by the FDA for use in the treatment of HFrEF with or without comorbid T2DM [11] . Consistent benefits were observed with a second SGLT-2 inhibitor, empagliflozin, in the EMPEROR-Reduced (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction) trial among patients with chronic HFrEF with or without T2DM. Among over 2000 patients in the contemporary CHAMP-HF (Change the Management of Patients with Heart Failure) registry with HFrEF and comorbid T2DM, the use of SGLT2 inhibitors (2.4%) was low, suggesting a large potential for therapeutic optimization [12] .

Core therapies, including β-blockers, mineralocorticoid receptor antagonists, renin-angiotensin-aldosterone system (RAAS) inhibitors, and angiotensin-receptor neprilysin inhibitors, have been shown to reduce mortality in HFrEF patients [13] . In addition, certain therapies appear to safely lower risk of hospitalization for HF, including vericiguat, a soluble guanylate cyclase stimulator [14] . Furthermore, several other therapies are being actively investigated to continue to expand the therapeutic armamentarium available for treatment of HFrEF, including omecamtiv mecarbil, a novel selective cardiac myosin activator [15] . Despite the growing list of evidence-based therapies available to improve outcomes in HFrEF, combination use in clinical practice has remained low. For instance, in a contemporary outpatient registry, < 1% of patients were simultaneously being treated with target doses of a β-blocker, mineralocorticoid receptor antagonist, and renin-angiotensin system inhibitor [16, 17] . The reasons underlying these therapeutic gaps are likely multifactorial, but they highlight inefficiencies with traditional approaches of stepwise medication changes in clinical practice. It is critical that simultaneous or near-simultaneous initiation of evidencebased therapies is considered to improve the rates of guideline-directed medical therapy and in turn afford patients with the life-prolonging benefits of combination medical therapies [18••] .

SGLT-2 inhibitors stand out as a drug class which uniquely fits into the current HF therapeutic regimen. In this review, we highlight their unique properties which may lend favorably to their efficient integration in the background of other HF therapies. We also discuss the unique aspects of SGLT-2 inhibitor dosing, lack of titration needs, effects on kidney function and electrolytes, diuretic activity, and safety in the high-risk perihospitalization window.

The period immediately after a worsening HF event has often been described as the "vulnerable phase" as it is characterized by high rates of readmission and mortality. A post-hoc analysis o f t h e E M P A -R E G O U T C O M E ( E m p a g l i f l o z i n Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial showed that the proportion of patients with a second HF readmission within 45, 60, and 90 days was almost 2 times higher in individuals treated with placebo compared with empagliflozin [19••] . Moreover, the proportions of patients with HF re-hospitalization or cardiovascular death and HF re-hospitalization or all-cause death were significantly higher in the placebo group versus empagliflozin at all time points. Similarly, in DAPA-HF, patients enrolled shortly after hospitalization for HF derived greater absolute benefits in reduction in HF events compared with patients randomized remote from a HF event or who had never been hospitalized [10 •• ] . These results indicate that SGLT-2 inhibitors may have 

Almost half of patients with T2DM are above 65 years of age [21] . As these individuals are at high risk of hypoglycemia, guidelines recommend less stringent glycemic control compared with younger patients [22] . SGLT-2 inhibitors pose a low risk of hypoglycemia (< 1%) in older adults, which is considerably lower than sulfonylureas and incretin-based therapies [23] . Moreover, older individuals typically have arterial stiffness leading to isolated systolic hypertension. SGLT-2 inhibitors have been shown to reduce oxidative stress and improve endothelial function leading to improvement in arterial stiffness [24, 25] . It is possible that SGLT-2 inhibitors may also have a favorable effect on blood pressure in patients with hypertension, leading to decreased polypharmacy. In the context of HF treatment, in DAPA-HF, dapagliflozin decreased the risk of mortality and worsening HF across a broad spectrum of age [26••] . Moreover, there was no significant difference in tolerability or adverse events between dapagliflozin and placebo in older individuals [26••] .

All SGLT-2 inhibitors are once daily medications and have minimal drug interactions. The main exception is canagliflozin, which is a P-glycoprotein substrate (modest inhibition); specifically, co-administration with digoxin may increase plasma levels of digoxin [27] . It is important to that note that while higher SGLT-2 inhibitor doses may offer greater glycemic control, large cardiovascular outcomes trials have shown little evidence exists for dose heterogeneity with respect to cardiovascular benefits in T2DM. In addition, completed and ongoing HF trials have tested fixed doses of SGLT-2 inhibitors without need for titration. Evidence to date from trials of T2DM suggest general class effects. Although the SGLT-2:SGLT-1 relative receptor affinity varies among the different agents, all CVOTs with SGLT-2 inhibitors have shown consistent benefit in preventing HF events among patients with at-risk populations with T2DM. Of note, the cardiovascular outcomes trial testing ertugliflozin has completed [28].

SGLT-2 inhibitors are associated with osmotic diuresis and natriuresis, which may be synergistic when used in combination with a loop diuretic [29••] . However, distinct from the widely used loop diuretics, SGLT-2 inhibitors may preferentially result in reduction in interstitial volume compared with intravascular volume, thus resulting in less compensatory RAAS activation [29••, 30] . In DAPA-HF, dosing of concomitant loop diuretics was only modestly lowered during the trial. It is suggested that clinicians actively monitor volume status after SGLT-2 initiation and consider decreasing loop diuretic dosing, especially if dizziness or orthostatic hypotension is encountered [31] .

Chronic kidney disease (CKD) is a key risk factor for the development and progression of HF [32] . The recent CARMELINA trial (Cardiovascular and Renal Microvascular Outcome Study with Linagliptin) showed that a substantially higher risk of HF hospitalization was observed in patients with estimated glomerular filtration rate (eGFR) < 60 mL/min per 1.73 m 2 compared with those with eGFR > 60 mL/min per 1.73 m 2 [33] . Multiple SGLT-2 inhibitors have shown kidney outcome benefits ( . In a meta-analysis of trials evaluating SGLT2 inhibitors for treatment of T2DM, these therapies were shown to reduce the risk of dialysis, transplantation, or mortality due to renal disease by 33%, and in fact were shown to decrease the risk of future episodes of acute kidney injury by 25% [37] . Furthermore, this observed benefit was present across all eGFR subgroups including eGFR < 45 mL/min per 1.73 m 2 . Indeed, the reduction in HF hospitalization was higher in patients with worse baseline kidney function; a 40% reduction in HF hospitalization was observed among patients with eGFR < 60 mL/min per 1.73 m 2 compared with 31% and 12% reductions in patients with eGFR ≥ 60 to < 90 mL/min per 1.73 m 2 and eGFR ≥ 90 mL/min per 1.73 m 2 , respectively [37] .

Pre-initiation kidney function is encouraged to be > 30 mL/ min per 1.73 m 2 for dapagliflozin when used for HF treatment as tested in the DAPA-HF trial. While glycemic effects appear to be limited at low eGFR, the HF benefits associated with dapagliflozin are anticipated across a broad eGFR range. Although SGLT-2 inhibitors affect a small expected initial dose-dependent reduction in eGFR within the first couple of weeks, eGFR subsequently stabilizes and is linked with kidney protective effects with long-term use [38] . As such, this modest decline in eGFR early after treatment initiation likely represents a pharmacodynamic effect rather than resulting in true kidney injury. Similar to considerations around initiation of RAAS inhibitors, the initiation of SGLT-2 inhibitors among patients with HF may be safest during periods with relative stability of eGFR [39] .

There are currently many therapies approved for glycemic control and HFrEF therapy. This can lead to considerable polypharmacy (with attendant non-compliance). While the optimal sequence of HFrEF therapies is uncertain, nearsimultaneous or clustered initiation of drugs may be feasible for many patients. One of the common reasons why guidelinedirected medical therapy is not started in clustered fashion by specialists is because of fears of hyperkalemia (due to RAAS inhibition) and low blood pressure. While patients with elevated blood pressures, including those with resistant hypertension [40] , may derive clinically important blood pressure reduction with SGLT-2 inhibitors, for most patients, SGLT-2 inhibitors cause minimal blood pressure lowering, with a mean reduction in systolic and diastolic blood pressure < 4 mmHg across various cardiovascular and kidney outcomes trials [39, 41, 42] . Moreover, SGLT-2 inhibitors are not associated with increased risk of hyperkalemia. Therapies which do not offer cardiovascular risk reduction or mortality benefit in HF, such as calcium channel blockers, should be deprescribed if low blood pressure with SGLT-2 initiation is a concern. As SGLT-2 inhibitors exert a diuretic effect, a dose adjustment in concomitant loop diuretics may be necessary based on clinical signs and symptoms during follow-up. Congestive signs and symptoms and orthostatic hypotension should be closely monitored.

In the DAPA-HF trial, 11% of the patients were on background angiotensin receptor neprilysin inhibition (ARNI) at enrollment. Subgroup analyses showed that the beneficial effect of dapagliflozin on HF outcomes was consistent independent of background ARNI use, suggesting additive and incremental effects [43] . Moreover, the mechanism of action of both drug types is distinct; hence, the use of both newer additions to the HFrEF regimen should be encouraged in HFrEF.

Among the large group of patients with HFrEF without concomitant T2DM, dapagliflozin did not appear to lower hemoglobin A1c compared with placebo [10••]. As such, there does not appear to be any concerns related to hypoglycemia among this population. For patients with concomitant T2DM, a modest glycemic effect is anticipated. The DAPA-HF trial did not have any protocolized modification of background antihyperglycemic therapies. When initiating SGLT-2 inhibitors in HFrEF and T2DM, certain antihyperglycemic therapies (such as sulfonylureas or dipeptidyl-peptidase-4 inhibitors) may be stopped or dose reduced. When polypharmacy is of high concern, combination formulations of metformin and SGLT-2 inhibitors are available and may be considered. While metformin has represented a foundational therapy for T2DM, about half of patients enrolled in the DAPA-HF trial were not on background metformin; these patients still derived significant clinical benefits. As such, when treating HFrEF, the staged introduction of metformin prior to SGLT-2 inhibitors is likely not required for cardiovascular benefit.

SGLT-2 inhibitors are generally well tolerated, including among patients with HF [44] . Serious adverse events were infrequent in the DAPA-HF trial. One of the more common side effects of SGLT-2 inhibitors is genital yeast infections, including vulvovaginal candidiasis and balanitis. These infections typically present early during treatment course and are more commonly seen in older women and uncircumcised men. These infections can often easily be treated with topical antifungal creams or single-dose oral antifungal therapy and typically do not require discontinuation of SGLT-2 inhibitor therapy. Patients should be specifically counseled about maintenance of perineal hygiene. In 2018, the FDA released a warning related to 12 cases of Fournier's gangrene, a rare but serious and potentially disfiguring perineal infection associated with SGLT-2 inhibitors [45].

Though rare, euglycemic diabetic ketoacidosis has also been associated with SGLT-2 inhibitors among patients with T2DM. As such, among patients with HF and comorbid T2DM, special attention should be given to HF patients who have poor oral intake and are expected to undergo elective surgeries. Canagliflozin, dapagliflozin, and empagliflozin should each be discontinued at least 3 days before scheduled surgery, while ertugliflozin should be discontinued at least 4 days before scheduled surgery [46] . Patients should be counseled about the common symptoms of ketoacidosis such as altered mental status, vomiting, and abdominal pain and should be advised to curb excessive alcohol intake. It is noteworthy that among patients with HF without T2DM, diabetic ketoacidosis does not appear to be a concern, and no cases were observed in the large DAPA-HF trial in this subset.

Currently, large clinical trials are evaluating the potential for the use of SGLT-2 inhibitors in HF with preserved ejection fraction (HFpEF). The ongoing DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure) and EMPEROR-Preserved (Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction) will provide further insights regarding the role of SGLT-2 inhibitors for this highrisk entity without current effective treatment options. SGLT-2 inhibitors may play a role in reversing adverse cardiac remodeling as observed in the EMPA-HEART (Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes) CardioLink 6 trial in which patients treated with empagliflozin experienced early and significant reduction in left ventricular mass regression [47••] . The ongoing PRESERVED-HF (Effects of Dapagliflozin on Biomarkers, Symptoms, and Functional Status in Patients with Preserved Ejection Fraction Heart Failure) and EMBRACE-HF (Empagliflozin Evaluation by Measuring Impact on Hemodynamics in Patients with Heart Failure) will give further information regarding the effect of SGLT-2 inhibitors on cardiac biomarkers, structure, and hemodynamics.

SGLT-2 inhibitors represent the most recent class of therapies that have been shown to modify clinical course and improve life expectancy among patients with HFrEF. Fixed-dose, once daily dosing without need for titration or frequent electrolyte/ kidney function monitoring all favor its safe and feasible introduction in multi-drug regimens across a broad range of HFrEF patients. Ongoing trials will evaluate if other patients with HF, including those with HFpEF and who are hospitalized for worsening HF, may similarly benefit from this class of therapies.

Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study

Global public health burden of heart failure

Trends in noncardiovascular comorbidities among patients hospitalized for heart failure: insights from the get with the guidelines-heart failure registry

Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure

Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes

Canagliflozin and cardiovascular and renal events in type 2 diabetes

Dapagliflozin and cardiovascular outcomes in type 2 diabetes

Dapagliflozin in patients with heart failure and reduced ejection fraction

Prescriber patterns of SGLT2i after expansions of U.S. Food and Drug Administration Labeling

Authors/task force members; document reviewers. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)

Vericiguat in patients with heart failure and reduced ejection fraction

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: rationale and design of GALACTIC-HF

Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry

Titration of medical therapy for heart failure with reduced ejection fraction

This study demonstrated that the ant icip ated aggregat e treat men t effects of early comprehensive disease-modifying pharmacological therapy are substantial and support the combination use of an angiotensin receptor neprilysin inhibitor, beta blocker, mineralocorticoid receptor antagonist, and SGLT-2

Empagliflozin is associated with a lower risk of post-acute heart failure rehospitalization and mortality

Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)

Diabetes and insulin resistance in older people

Glycemic targets: standards of medical care in diabetes 2020

Inhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy

Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus

This study provides evidence that dapagliflozin decreases the risk of mortality and worsening heart failure even in older individuals

Practical guide to prescribing sodium-glucose cotransporter 2 inhibitors for cardiologists

This study shows that SGLT-2 inhibitors are associated with significant osmotic diuresis and natriuresis

Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis

Use of sodium glucose cotransporter 2 inhibitors in the hands of cardiologists

Use of sodiumglucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure

Linagliptin effects on heart failure and related outcomes in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

In this trial, canagliflozin reduced the risk of a composite of doubling of serum creatinine, end stage kidney disease, or mortality due to cardiovascular or renal cause by 30%

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors

Practical considerations for the use of sodium-glucose co-transporter 2 inhibitors in heart failure

Empagliflozin for patients with presumed resistant hypertension: a post hoc analysis of the EMPA-REG OUTCOME trial

Effect of canagliflozin use on body weight and blood pressure at one-year follow-up: a systematic review and meta-analysis

Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension

Effects of dapagliflozin in DAPA-HF according to background heart failure therapy

SGLT-2 inhibitors in heart failure: current management, unmet needs, and therapeutic prospects

Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

Conflict of Interest Muhammad Shahzeb Khan has no disclosures to report. Muthiah Vaduganathan is supported by the KL2/Catalyst Medical Research Investigator Training award from Harvard Catalyst (NIH/ NCATS Award UL 1TR002541); serves on advisory boards for Amgen, AstraZeneca, Baxter Healthcare, Bayer AG, Boehringer Ingelheim, Cytokinetics, and Relypsa; and participates on clinical endpoint committees for studies sponsored by Galmed, Novartis, and the NIH.Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.